Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Data-Standards Landslide: CDISC’s Model Wins Docket Comment Contest

This article was originally published in The Pink Sheet Daily

Executive Summary

Overwhelming number of stakeholders urge FDA to choose the Clinical Data Interchange Standards Consortium’s Operational Data Model instead of the competing Health Level 7 standard for clinical data submissions.

You may also be interested in...



FDA’s Data Format Standards Approaching Cost-Benefit Analysis Stage

The agency sets a meeting for November and wants comments in advance on potential candidates for a format that will reduce the need for data integration steps between its various systems.

Draft Common Data Elements Connect MS, Other Neurological Diseases

NIH’s National Institute of Neurologic Disease and Stroke coordinated a project to get experts to agree on a set of common data elements for use in studies of different aspects of multiple sclerosis.

Efficacy Standards For 55 Diseases In 5 Years: FDA, Critical Path And CDISC’s Ambitious Plan

Building on the Alzheimer’s disease Therapeutic Area Standard, the groups hope to create measurement standards for clinical trials in a variety of therapeutic areas, but funding remains an acute challenge. In order to succeed, each project needs to be faster and cheaper than the Alzheimer’s effort.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS073407

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel